Press Releases

BioReliance news and press releases. Please contact us if you would like further information about BioReliance or services provided by BioReliance.

Showing 1-10 of 10 results.
Release Year
Title
Date

ST. LOUIS – Sept. 4, 2013 – Sigma-Aldrich® Corporation’s (NASDAQ: SIAL) BioReliance® (www.bioreliance.com), the biologics and early-development services business under SAFC (www.sigmaaldrich.com/safc), has opened a new Clearance Services facility in Rockville, MD.

This world-class facility, commissioned on August 1, 2013, allows BioReliance to offer increased capacity and flexible scheduling while maintaining its core focus on providing industry-leading quality, expertise and value. The new U.S. facility more than doubles the amount of space available to clients to conduct their critical downstream bioprocessing studies.

Designed with input from clients and built to complement BioReliance’s global viral clearance services capabilities, the Rockville facility features four large clearance suites with modular layouts that allow for customized laboratory setups. All studies performed at the facility are completely secure and supported by dedicated scientists and state-of-the-art chromatography equipment, such as GE Healthcare’s ÄKTA® avant. Every project is fully compliant with applicable global guidelines and regulations, including those from the U.S. Food and Drug Administration and European Medicines Agency. Completed studies receive a consolidated report that includes comprehensive titration and/or process data. BioReliance has already successfully conducted several client studies and quality audits in the new facility.

“Combining our deep knowledge and proven experience with a global investment in modern facilities and equipment enables BioReliance to offer robust validation packages and proprietary CompleteClearance™ services to our clients. It’s all about simplifying the viral clearance process through an unrivaled combination of scientific expertise, client-focused service and decades of experience,” said Archie Cullen, president of BioReliance. “Any time a client comes to work with us, they are assured that their study is expertly designed and performed by personnel that have participated in thousands of successful studies in support of clinical and commercial biopharmaceutical products.”

Clients using BioReliance’s U.S. facility will have access to a wide range of resources, including personalized modular laboratory suites with spacious, technology-enabled lounges, unique “suite-to-lounge” monitoring, and support from industry-leading personnel.

The Rockville Clearance Services facility investment completes BioReliance’s upgrade to its global offering designed to deliver a total client solution and experience. The Stirling, Scotland (U.K.), Clearance Services laboratories were completely renovated and expanded in 2011. To learn more about BioReliance’s new Clearance Services facilities, or to inquire about services, click here.

The foregoing release contains forward-looking statements that can be identified by terminology such as “will behave” or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. There can be no guarantee that the products and services in SAFC’s product and service offerings will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products or services will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding these products and services could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company’s ability to obtain or maintain patent, trademark or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company’s assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich’s current Form 10-K on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About BioReliance by SAFC: Sigma-Aldrich Corporation acquired BioReliance in January 2012 to provide customers access to a powerful, single-point provider whose products and services span the drug discovery, development and commercialization pipeline. As part of the SAFC business unit, BioReliance is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized toxicology and animal health services. BioReliance has more than 700 employees and has laboratory operations in Rockville, Md. and Scotland. For more information, visit www.bioreliance.com.

About SAFC: SAFC Commercial, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life sciences and high-technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline utilizing its global "Centers of Excellence" and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high-technology applications, critical raw materials and extensive biologics safety testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.sigmaaldrich.com/safc.

About Sigma-Aldrich: Sigma-Aldrich, a leading life sciences and high-technology company focused on enhancing human health and safety, manufactures and distributes more than 200,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units – Research, Applied and SAFC Commercial – Sigma-Aldrich is committed to enabling science to improve the quality of life. The company operates in 38 countries, has more than 9,000 employees worldwide and had sales of $2.6 billion in 2012. For more information about Sigma-Aldrich, please visit www.sigmaaldrich.com.

©2013 Sigma-Aldrich Co. LLC. All rights reserved. SAFC and BioReliance are trademarks of Sigma-Aldrich Co. LLC or its affiliates, registered in the U.S. and other countries. ÄKTA is a registered trademark of GE Healthcare Bio-Sciences AB.

# # # 

September 24, 2013

ST. LOUIS – October 16, 2014 – BioReliance® (www.bioreliance.com), Sigma-Aldrich Corporation’s (NASDAQ: SIAL) biologics and early-development services business under SAFC® Commercial (www.sigmaaldrich.com/safc), has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services for pharmaceutical, chemical and industrial consumer products to its service offering. The broad set of highly predictive assays use a novel suite of genetically modified cell lines created with CompoZr® zinc finger nuclease (ZFN), a Sigma-Aldrich proprietary technology.

“The new in vitro ADME and toxicology testing services complement the existing genetic toxicology testing portfolio at BioReliance, and have been designed to meet the growing demand for more predictive human cell-based assays,” said Daniel Aparicio, Executive Director and General Manager of Toxicology at BioReliance. “The services are a valuable evolution from our synergies with Sigma-Aldrich products, and have been designed to decrease risk and total cost of ownership for customers in the discovery phase.”

Designed in accordance with guidelines from agencies like the FDA, EMA and ITC, the assays help customers predict outcomes by determining levels of permeability, transport, metabolism and toxicity in a drug product. Each cell line is tested for functionality, which means that customers in discovery phases can more easily isolate any compounds that may affect product development before it can affect the safety or efficacy of a possible drug product.

“A shift in emphasis to testing in earlier phases of drug discovery and development, increasing efforts to reduce cost, stricter regulatory guidance, and a reduction in animal usage is driving the demand for more predictive in vitro ADME and Tox assays and services,” said Paul Brooks, Ph.D, Head of Discovery Research Services at Sigma-Aldrich. “Our expanding portfolio of cell lines, available as products and now services is creating the most comprehensive and accessible platform for in vitro ADME and toxicology testing in the market.”

For more information about BioReliance’s in vitro ADME and toxicology testing services, please click here.

About BioReliance by SAFC: As part of the Sigma-Aldrich Corporation, operating under the SAFC Commercial business unit, BioReliance is a key component of the Company's commercial life science services portfolio. With locations worldwide, BioReliance offers more than 1,000 tests and complementary services related to biologics safety testing and specialized toxicology. For more information, visit www.bioreliance.com.

About SAFC: SAFC Commercial, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life science and high-technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline using its global "Centers of Excellence" and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high-technology applications, critical raw materials and extensive biologics safety testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.sigma-aldrich.com/safc.

About Sigma-Aldrich: Sigma-Aldrich, a leading life science and high-technology company focused on enhancing human health and safety, manufactures and distributes 230,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units—Research, Applied and SAFC Commercial—Sigma-Aldrich is committed to enabling science to improve the quality of life. The company operates in 37 countries, has more than 9,000 employees worldwide and had sales of $2.7 billion in 2013. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.

©2014 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich, SAFC, BioReliance and CompoZr are trademarks of Sigma-Aldrich Co. LLC or its affiliates, registered in the U.S. and other countries.

# # #

 

October 16, 2014

ST. LOUIS – August 28, 2013 – Sigma-Aldrich® Corporation’s (NASDAQ: SIAL) BioReliance® (www.bioreliance.com), the biologics and early-development services business under SAFC® (www.sigmaaldrich.com/safc), has qualified the Big Blue® Mouse Transgenic Rodent Mutation (TRM) assay to meet the new Organization for Economic Co-Operation and Development (OECD) Test Guideline 488 requirements for evaluation of in vivo mutagenicity.

Big Blue is identified in OECD Test Guideline 488, as well as recommended by various agencies and expert groups, including the European Chemicals Agency, as an accepted assay for evaluating mutagenicity in somatic and male germ cell tissues. BioReliance confirms that the Big Blue Mouse TRM assay service is immediately available.

BioReliance acquired the exclusive ownership of the Big Blue TRM assay and rodents from Agilent in March 2013. The assay service fulfills a specific need of pharmaceutical and chemical companies by providing a unique confirmatory test for drugs and chemicals that initially test positive in in vitro mutation assays.  

“We are pleased to offer this critical service to our clients,” stated Robert Young, study director for TRM assays at BioReliance. “Our company played a key role in the development and validation of the model in the early 1990s. We have now expanded our expertise by updating and qualifying the assay to meet the requirements of OECD 488, additional regulatory guidelines and the current needs of our clients. This new service complements BioReliance’s existing portfolio of comprehensive genotoxicity testing methods.”

BioReliance will present a scientific poster detailing the Big Blue TRM qualification studies at the upcoming EUROTOX Conference (Sept. 1-4, 2013, Interlaken, Switzerland). Big Blue TRM experts will be available for individual consultation at this event and at the Environmental Mutagenesis and Genomics Society Conference (Sept. 21-25, 2013, Monterey, Calif., U.S.).

To read about the exclusive license of Big Blue earlier this year, click here.  

For more information on the Big Blue Mouse TRM assay service, click here.

The foregoing release contains forward-looking statements that can be identified by terminology such as “will be,” “anticipates,” “believes” or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. There can be no guarantee that the products and services in SAFC’s product and service offerings will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products or services will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding these products and services could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company’s ability to obtain or maintain patent, trademark or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company’s assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich’s current Form 10-K on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About BioReliance by SAFC: Sigma-Aldrich Corporation acquired BioReliance in January 2012 to provide customers’ access to a powerful, single-point provider whose products and services span the drug discovery, development and commercialization pipeline. As part of the SAFC business unit, BioReliance is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized toxicology and animal health services. BioReliance has more than 700 employees and has laboratory operations in Rockville, Md. and Scotland. For more information, visit www.bioreliance.com

About SAFC: SAFC Commercial, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life sciences and high-technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline utilizing its global “Centers of Excellence” and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high-technology applications, critical raw materials and extensive biologics safety testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.sigmaaldrich.com/safc.                                                                                                                                                                      

About Sigma-Aldrich: Sigma-Aldrich, a leading life sciences and high-technology company focused on enhancing human health and safety, manufactures and distributes more than 200,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units—Research, Applied and SAFC Commercial—Sigma-Aldrich is committed to enabling science to improve the quality of life. The company operates in 38 countries, has more than 9,000 employees worldwide and had sales of $2.6 billion in 2012. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.

©2013 Sigma-Aldrich Co. LLC. All rights reserved. SAFC is a trademark of Sigma-Aldrich Co. LLC or its affiliates, registered in the U.S. and other countries.

# # #

 

August 28, 2013

  • Merck KGaA to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion (€13.1 billion)
  • Acquisition expands EMD Millipore’s global reach, increasing the company’s presence in North America and adding exposure to fast-growing Asian markets
  • Customers benefit from broader offering of complementary products and capabilities and leading e-commerce platform in the industry
  • Merck KGaA plans to maintain significant presence in St. Louis, MO, and Billerica, MA
  • Life Science contribution to Merck KGaA earnings more than doubles
  • Transaction expected to be immediately accretive to EPS pre and EBITDA margin
  • Merck KGaA to host media conference call today at 8:00 AM EDT / 2:00 PM CET

Darmstadt, Germany and St. Louis, MO, September 22, 2014 – Merck KGaA, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich today announced that they have entered into a definitive agreement under which Merck KGaA, Darmstadt, Germany, will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion), establishing one of the leading players in the $130 billion global life science industry.

Click here for complete press release.

September 22, 2014

ST LOUIS, MO – March 5, 2013 – Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced that BioReliance® (http://www.bioreliance.com), the biologics and early development services business under SAFC® (www.safcglobal.com), has signed an agreement to acquire the colonies required for the Big Blue® transgenic rodent mutation (TRM) assay and to obtain a license to its associated trademark from Agilent Technologies.

TRM assays, which measure mutation frequency in any tissue, are the first in vivo genetic toxicology mutation assays to be approved by the Organization for Economic Co-Operation and Development (OECD), meeting Testing Guideline 488. BioReliance is now the owner of Big Blue®, mutation models and the exclusive supplier of testing services based on this model. 

“It is often of critical importance to use an in vivo mutation assay in order to assess human risk in drug development and chemical manufacturing. Big Blue® is such an assay and one we are intimately familiar with, having been part of the initial co-development team in the 1990s,” stated Daniel Aparicio, Executive Director and General Manager of Early Development Services at BioReliance. “Based on feedback from our customers and from the market in general, we believe there will be an ever-increasing demand for transgenic rodent assays and we are delighted to be able to bring that capability to customers on the back of this agreement.”

BioReliance is now focused on completing the transfer of colonies and cell lines from Agilent and building full capacity and capability to perform the Big Blue® assay. BioReliance is in the process of re-qualifying the assay to meet new regulatory requirements and anticipates that Big Blue® testing services will be commercially available in the second half of the year.

BioReliance has been a leading provider of genetic toxicology testing services over the past two decades and continues to innovate and offer the latest technologies to help ensure the safety of pharmaceuticals and chemical compounds. The Big Blue® Testing Assay was originally validated by BioReliance to use as a GLP regulatory submission assay to detect chromosomal and/or gene mutations in collaboration with Agilent in the early 90s.

To learn more about BioReliance by SAFC, please visit: www.bioreliance.com

The foregoing release contains forward-looking statements that can be identified by terminology such as “will be," "anticipates", “believe” or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. There can be no guarantee that the products and services in SAFC’s product and service offerings will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products or services will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding these products and services could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent, trademark or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company’s assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich’s current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About BioReliance by SAFC: BioReliance was acquired by Sigma-Aldrich Corporation, in January, 2012 to supply customers access to a powerful, single-point provider whose products and services span the drug discovery, development and commercialization pipeline. As part of the SAFC business unit, BioReliance is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized toxicology and animal health services. BioReliance has over 700 employees and has laboratory operations in Rockville, MD and Scotland.For more information, visit www.bioreliance.com

About SAFC: SAFC, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life science and high technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline utilizing its global "Centers of Excellence" and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high technology applications, critical raw materials and extensive biologics safety testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology SAFC manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.

©2013 Sigma-Aldrich Co. LLC. All rights reserved. BioReliance and SAFC are trademarks of Sigma-Aldrich Co. LLC or its Affiliates, registered in the US and other countries.

March 03, 2013

ROCKVILLE, MD – November 30, 2012 -- Dr. Marilyn Aardema, Chief Scientific Advisor for Toxicology at BioReliance was recently named the recipient of awards for her outstanding achievements during her distinguished career. The two awards from the Environmental Mutagen Society (EMS) and the Genetic Toxicology Association (GTA), represent highest honors conferred by these societies.

BioReliance Corporation is a leading contract services company in the area of product safety.  Its clients include pharmaceutical, biotechnology, chemical, consumer product, medical device and academic organizations.

In September, Dr. Aardema was named the recipient of the 2012 Alexander Hollaender Award by the Environmental Mutagen Society (EMS). The Alexander Hollaender Award is conferred in recognition of long‐standing service in the application of the principles and techniques of environmental mutagenesis to protect human health and is the highest honor bestowed by EMS. In October, Dr. Aardema won the highest award from the paramount society for Genetic Toxicology, the Genetic Toxicology Association (GTA), when she was named the Excellence in Science Award winner for 2012, conferred to a member of the GTA in recognition of outstanding contributions in the applications of Genetic Toxicology and for having provided exemplary representation of the three pillars of GTA:  Industry, Regulatory and Basic research.

Dr. Aardema received her PhD in Genetics from The University of Tennessee‐Oak Ridge Graduate School of Biomedical Sciences, and went on to establish herself as an internationally recognized expert and highly influential leader in applied genetic toxicology. In over 30 years of devoted service to her field, Dr. Aardema has over 75 publications, has lead international consortia and contributed to numerous societies, working groups and scientific panels. Most recently as the Chief Scientific Advisor for Toxicology at BioReliance, Dr. Aardema has provided important impact and innovation through the pioneering development of 3D skin culture models and alternative in vitro testing strategies in genetic toxicology.

About BioReliance:
BioReliance was acquired by Sigma-Aldrich Corporation, in January, 2012 to supply customers access to a powerful, single-point provider whose products and services span the drug discovery, development and commercialization pipeline. As part of the SAFC business unit, BioReliance is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized toxicology and animal health services. BioReliance has over 700 employees and has laboratory operations in Rockville, MD and Scotland. For more information, visit www.bioreliance.com.

About SAFC: 
SAFC, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life science and high technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline utilizing its global "Centers of Excellence" and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high technology applications, critical raw materials and extensive biologics safety testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.safcglobal.com.

# # #

November 30, 2012

Rockville, MD, USA – January 9, 2012 – BioReliance, a leading provider of global biopharmaceutical testing services, announced today that it has agreed to be acquired by Sigma-Aldrich Corporation (NASDAQ:SIAL). 

Avista Capital Partners, the majority owner of BioReliance Holdings, Inc., agreed to sell the company for $350 million in cash.  The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.

BioReliance provides critical services that include biologics testing, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science clients worldwide.  BioReliance’s service offering helps facilitate drug development, manufacturing and commercialization activities.  The Company’s ability to develop and execute global testing protocols in compliance with various regulatory standards enables BioReliance’s clients to register products with regulatory agencies worldwide.

Sigma-Aldrich is a leading Life Science and High Technology company.  Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing.

Commenting on the transaction, BioReliance’s President and CEO Charles Harwood stated, “The acquisition of BioReliance by Sigma-Aldrich creates one of the broadest product and service offerings for the development and manufacture of biological drugs.  In addition, BioReliance’s Specialized Toxicology and Animal Health Services segments are complementary to other Sigma-Aldrich product and technology areas.”

Avista Capital Partners acquired BioReliance in 2007.  With regards to the acquisition of BioReliance by Sigma-Aldrich, Avista Partner and President David Burgstahler commented, “BioReliance is a world-class organization led by an outstanding team of seasoned life sciences professionals that has demonstrated success through impressive growth, scientific innovation and exceptional customer service.  Avista is committed to work with Sigma-Aldrich to ensure the successful transition of BioReliance and believes that the addition of BioReliance’s capabilities and service portfolio will allow Sigma-Aldrich to significantly enhance value to its clients and stakeholders.”

J.P. Morgan Securities LLC acted as financial advisor and Weil, Gotshal & Manges LLP served as legal advisor to BioReliance for this transaction.

About BioReliance BioReliance Corporation is a leading provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologic testing, specialized toxicology and animal health services.  Founded in 1947, BioReliance is headquartered in RockvilleMaryland, with laboratory operations in Rockville and Scotland and offices in TokyoJapan, and BangaloreIndia. The Company employs more than 650 people globally.  For more information, visit www.bioreliance.com.

About Avista Capital Partners Avista Capital Partners is a leading private equity firm with over $4 billion under management with offices in New York, Houston, and London. Founded in 2005, Avista’s strategy is to make controlling or influential minority investments in growth-oriented energy, healthcare, media, industrial and consumer businesses. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. For more information visit: www.avistacap.com.

# # #

January 09, 2012

ROCKVILLE, MD – September 12, 2011 -- BioReliance announced today that it is adding new personnel to enhance both its Genetic Toxicology and Mammalian Toxicology operations with three scientific experts, Mr. Timothy Lawlor, Dr. Rohan Kulkarni, and Ms. Marie McKeon.

BioReliance Corporation is a leading contract services company in the area of product safety.  Its clients include pharmaceutical, biotechnology, chemical, consumer product, medical device and academic organizations.

Mr. Lawlor joins BioReliance as the Director of Study Management for Genetic Toxicology, managing both Principal Scientists and Study Coordination. Mr. Lawlor has over thirty years of experience in contract research organizations and holds a Masters Degree from Temple University.  Since 1977 he has worked in the field of Genetic Toxicology as a scientist and study director and is globally recognized for his leadership and expertise.

Dr. Kulkarni has been named Senior Scientist in Genetic Toxicology. Dr. Kulkarni will serve as study director for studies in the In Vitro and In Vivo Cytogenetics Laboratories. Dr. Kulkarni received his PhD from Wayne State University working with Dr. James Tucker and has recently completed a postdoctoral fellowship at FDA, NCTR (National Center for Toxicological Research) working in Dr. Suzanne Morris’ laboratory.

Ms. McKeon has been named Principal Scientist in Mammalian Toxicology. As a board certified regulatory toxicologist and the author of numerous publications on in vitro and in vivo toxicology, Ms. McKeon is ideally suited to serve as a study director at BioReliance. Ms. McKeon holds two Masters Degrees, from The George Washington University and New York University, and has over 30 years of experience in toxicology.

“It is with great pleasure that I welcome these new scientists to our team at BioReliance,” said President and CEO, Charles C. Harwood, Jr. “Beginning with the addition of Dr. Marilyn Aardema as Chief Scientific Officer for Toxicology in late 2010, we have continued to expand and enhance our specialized toxicology operations. The expertise added by these newest additions is representative of the quality of our entire staff.” 

About BioReliance
BioReliance Corporation is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized toxicology and animal health services.  Founded in 1947, BioReliance is headquartered in Rockville, Maryland, with laboratory operations in Rockville and Scotland and offices in Tokyo, Japan, and Bangalore, India. The Company employs more than 650 people globally.  For more information, visit www.bioreliance.com.     

# # #

October 11, 2011

BioReliance has been awarded a contract under the U.S. EPA’s ToxCast™ program.  This 5 year contract encompasses genetic toxicology screening of environmental chemicals for potential toxicity and has the potential to evaluate 10,000 chemicals.

ROCKVILLE, MD – August 4, 2011 -- BioReliance announced today that it has been awarded a contract under the U.S. Environmental Protection Agency’s (EPA) Computational Toxicology Research Program called ToxCast™. This contract for the testing of “High Throughput Complex Cell Co-Culture Systems” encompasses genetic toxicology screening of environmental chemicals for potential toxicity.

BioReliance Corporation is a leading contract services company in the area of product safety. Its clients include pharmaceutical, biotechnology, chemical, consumer product, medical device and academic organizations.

In the initial scope of this contract, BioReliance will be testing 1,000 chemicals under Phase II of the Toxicity Forecaster (ToxCast™) program. These chemicals come from a broad range of sources, including industrial and consumer products, food additives and drugs, that have been compiled under the Tox 21 collaboration between the EPA, National Institutes of Environmental Health Sciences/National Toxicology Program, National Institutes of Health (NIH)/National Human Genome Research Institute, NIH Chemical Genomics Center and the Food and Drug Administration. This contract between BioReliance and the EPA includes the option to expand the program over the course of 5 years and test up to 10,000 chemicals.

“BioReliance has long employed various compound screening methods to understand mechanism of action and predict potential human hazard,” said Global Toxicology Technical Specialist, Robert Young. “BioReliance welcomes the opportunity to utilize our experience and expertise to effectively predict how chemicals will affect biological responses. The data generated from our innovative chemical testing methods will be combined with data from other screening methodologies to enable the EPA to make risk-assessments of many chemicals that have not previously been well characterized.”

“BioReliance is proud to participate in this significant program,” said President and CEO, Charles C. Harwood, Jr. “This program will employ the broad scientific and operational capabilities of BioReliance to deliver to the EPA the same timely, accurate, and cost-effective results we are committed to providing to all of our clients – so they can make informed assessments about the safety of chemical products for human use.”

About BioReliance
BioReliance Corporation is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized toxicology and animal health services. Founded in 1947, BioReliance is headquartered in Rockville, Maryland, with laboratory operations in Rockville and Scotland and offices in Tokyo, Japan, and Bangalore, India. The Company employs more than 650 people globally. For more information, visit www.bioreliance.com.


# # #

August 04, 2011

ROCKVILLE, MD – March 3, 2011 --

BioReliance announced today that it is expanding its Genetic Toxicology operations by adding two experienced scientists in this area. This expansion includes the additions of Dr. Leon F. Stankowski, Jr. and Dr. Shambhu Roy.

BioReliance Corporation is a leading contract services company in the area of product safety. Its clients include pharmaceutical, biotechnology, chemical, consumer product, medical device and academic organizations.

Dr. Stankowski joins BioReliance as a Principal Scientist and Program Consultant for Genetic Toxicology. Dr. Stankowski received his PhD in Biomedical Sciences (Genetics) from the University of Tennessee-Oak Ridge. Since 1984 he has worked in the field of Genetic Toxicology for both Pharmaceutical and contract services companies and is globally recognized in the field. He will serve BioReliance as both a study director and as principal scientific support for clients requiring advice on program design.

Dr. Roy has been named Senior Scientist in the Genetic Toxicology Department. Dr. Roy will serve as study director and have overall scientific oversight of the In Vitro Cytogenetics laboratory of the Toxicology division. Dr. Roy has over 20 years experience in Genetic Toxicology and received his PhD from Gujarat University in Ahmedabad, India. Dr. Roy was a post-doctoral research fellow with Dr. David Eastmond (UC Riverside), and has spent his career in contract service organizations. “I am delighted that these talented scientists are able to join our team at BioReliance,” said President and CEO, Charles C. Harwood, Jr. “The additions of Dr. Stankowski and Dr. Roy, along with the recent addition of Dr. Marilyn Aardema as Chief Scientific Officer for Toxicology, will serve to ensure that BioReliance moves forward as the leader in the field of Genetic Toxicology.”


About BioReliance

BioReliance Corporation is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized toxicology and animal health diagnostics. Founded in 1947, BioReliance is headquartered in Rockville, Maryland, with laboratory operations in Rockville and Scotland and offices in Tokyo, Japan, and Bangalore, India. The Company employs more than 600 people globally. For more information, visit www.bioreliance.com.


# # #

March 03, 2011

Contact Us: 1.800.756.5658

Search Sigma-Aldrich.com

Sigma aldrich

Copyright © 2015 Sigma-Aldrich Co. LLC.  All Rights Reserved.  Reproduction of any materials from the site is strictly forbidden without permission.  Sigma-Aldrich brand products are sold exclusively through Sigma-Aldrich Co. LLC.  Terms | Privacy | Site Map